SCHEMBL31015405

SCHEMBL31015405

COc1cc(B2OC(C)(C)C(C)(C)O2)c2cnn(C3CCCCO3)c2c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE1B Q01064 9/20 0.36
▸ PDE1C Q14123 9/20 0.36
▸ PDE1A P54750 8/20 0.36
▸ RXRA P19793 1/20 0.36
▸ RXRB P28702 1/20 0.36
▸ RXRG P48443 1/20 0.36
▸ CYP4F2 P78329 2/20 0.34
▸ CYP4A11 Q02928 2/20 0.34
▸ UCHL1 P09936 1/20 0.34
▸ FGFR1 P11362 2/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ ATR Q13535 2/20 0.33
▸ FGFR2 P21802 1/20 0.32
▸ FGFR4 P22455 1/20 0.32
▸ FGFR3 P22607 1/20 0.32
▸ KDR P35968 1/20 0.32
▸ FLT3 P36888 1/20 0.32
▸ HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23043800 0.86 CYP4F2 (0.38) PDE1BPDE1CPDE1ARXRARXRB
SCHEMBL30392077 0.86 CYP4F2 (0.38) PDE1BPDE1CPDE1ARXRARXRB
SCHEMBL30858862 0.85 RXRA (0.37) PDE1BPDE1CPDE1ARXRARXRB
SCHEMBL20581028 0.85 RXRA (0.37) PDE1BPDE1CPDE1ARXRARXRB
SCHEMBL31093701 0.85 CYP4F2 (0.37) PDE1BPDE1CPDE1ARXRARXRB
SCHEMBL15229935 0.82 RXRA (0.35) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL30797632 0.82 CREBBP (0.35) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL27165299 0.82 RXRA (0.35) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL138511 0.82 RXRA (0.37) PDE1BPDE1CPDE1ARXRARXRB
SCHEMBL25795327 0.81 RXRA (0.40) PDE1BPDE1CPDE1ARXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250002475-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS EPICS THERAPEUTICS (BE) 2025-01-02 — — US disclosed
US-12091400-B2 Piperidine derivatives as METTL3 inhibitors EPICS THERAPEUTICS (BE) 2024-09-17 — — US disclosed
US-20240270716-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS EPICS THERAPEUTICS (BE) 2024-08-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240270716-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS METTL3, METTL16, DIMT1 PDE1B 3075/4885PDE1C 3849/4885PDE1A 3186/4885
US-20250002475-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS METTL3, METTL16, DIMT1 PDE1B 3075/4885PDE1C 3849/4885PDE1A 3186/4885
US-12091400-B2 Piperidine derivatives as METTL3 inhibitors METTL3, METTL16, DIMT1 PDE1B 3075/4885PDE1C 3849/4885PDE1A 3186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback